Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Firms Alarmed By Australian Plans To Raise GMP Fees

Executive Summary

Medicines Australia says that none of the options for recovering GMP costs set out in its consultation earlier this year are suitable, although views among individual pharmaceutical companies differ.

You may also be interested in...

Australia's Revised GMP Fee To Apply From 1 July

Under Australia's new fee model for good manufacturing practice inspections, domestic manufacturers will no longer be able to accrue unbillable “free inspection hours.” Any residual free hours will expire on July 1, 2020.

Australia Plans Changes To GMP Fee Structure To Help Cover Costs

Australia is planning changes to the way it charges pharmaceutical manufacturers for activities related to good manufacturing practice, such as inspections, because the current arrangements do not allow it to recover its costs.

Joint Tendering Creates ‘Attractive Nordic Market’

Joint tendering among Nordic countries can help reduce shortages of older, off-patent medicines. 





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts